EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

November 15, 2024

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 66 min

Earnings Call Speaker Segments

Operator

operator
#1

Good afternoon, or good morning, everyone, and welcome to the conference call on El.En.'s financial results for the third quarter of 2024. This call is being recorded, and there will also be a chance to ask questions at the end of it. Joining me are Andrea Cangioli, El.En.'s CEO, and Enrico Romagnoli, El.En.'s Chief Financial Officer and Investor Relator. Before we start, please be aware that management will make remarks on this call regarding future expectations, plans, and prospects, as well as forward-looking statements. Some statements made here, including any that address the company's beliefs, plans, objectives, estimates, or expectations concerning possible future results or events, are forward-looking statements. Such statements carry known or unknown risks, among them general economic and business conditions and conditions in the industry where we operate, and we could be affected if our assumptions prove inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance, or achievements could differ materially from those expressed or implied by these forward-looking statements. The company assumes no obligation regarding the contents of these remarks, nor to update any forward-looking statements to reflect events or circumstances that might arise after today's date. At the conclusion of the presentation, should you wish to ask a question, please put it in the chat or raise your virtual hand.

Operator

operator
#2

You’ll get the floor in the order requests come in. That said, this time I’d like to hand things over to Andrea Cangioli. Andrea, please go ahead.

Andrea Cangioli

executive
#3

Many thanks, Bianca. Good afternoon, everyone. I appreciate your joining this call arranged to discuss the interim financial report we released yesterday, dated September 30, 2024. Please excuse my weak voice — I'll do my best to read and speak as clearly as I can. We're happy with how the quarter performed overall; it brought a rebound in revenues and profitability and is bringing the 2024 results, particularly on the income from operation metrics, back in line with last year's financial results. During that same period and over recent days, some notable steps have been taken to give our laser cutting division a chance at sustained growth, laying the groundwork for handing the division over to a highly qualified party that will assume responsibility for managing it, while we also gain from our ongoing commitment to support our companies' activities in our new capacity as a minority stakeholder. We went into this topic in depth on the call held earlier this week, and I'll offer a few brief remarks on it later in this call. Turning back to the summary financial results shown in the presentation, revenues remain 5% below 2023, though they rose 4% in the quarter.

Andrea Cangioli

executive
#4

EBIT for the quarter rose almost 30% versus 2023, and after nine months it came in at EUR 50.8 million, which is just 1.7% below the 2023 figure for that same period. Our medical business managed to grow revenues during the nine months, whereas revenue targets were not met in the industrial sector, which was down 16%. On EBIT, we are squarely on track to deliver the full-year increase we guided you to. Turning to how 2024's EBIT breaks down by sector versus 2023, better profitability in the industrial sector plus the impact of certain one-time events affecting both sectors are making industrial's contribution more significant than it was in 2023. We had a very strong quarter in some business areas, and that let us offset, in the consolidated results, softer performance elsewhere. As in the first half of this year, market conditions were favorable in some areas, yet in quite a few geographies and applications they were nowhere near favorable. International markets supported our growth across most of the businesses — meaning each application or geographic market combination — with three notable exceptions. Demand in the U.S. for medical devices proved weaker than our expectations.

Andrea Cangioli

executive
#5

So, product innovation and solid partnerships with our valued distributors helped us deliver a moderately satisfying result in that area. Demand in the Italian market for industrial applications was very weak, given the unfavorable economic climate and the particular effect of a poorly handled transition between certain expiring tax incentives and other new ones — specifically the so-called Industry 4.0 and 5.0 — which created a genuine gap in order bookings and deliveries during the first six months of the year. Cutlite Penta in the laser cutting market and Lasit in the laser marking market were forced to report revenue shortfalls of up to 40% compared with 2023 for the year, far beyond what you'd expect in a year of mildly declining demand. The good news here is that order bookings appear to be recovering quite smoothly now that the new incentives have been clearly defined, which removes the risk and uncertainties around the investment case for our customers. The third area of difficulty was the Chinese market for laser cutting systems, again very weak, which drove our subsidiaries' domestic revenues down 33% and kept the subsidiaries from materially improving their profitability this year, as we had hoped and expected, planned and worked for through the robust cost-saving activities carried out starting in the second half of last year.

Andrea Cangioli

executive
#6

Much more encouraging and full of potential was how the international market received our products. Sales outside Italy for Cutlite rose by roughly 50%, and for Penta Laser, sales outside mainland China went up by approximately the same amount, and those sales, with their higher profit margins compared with domestic sales, had a positive impact on our profitability, very clear at Cutlite Penta, which, despite a 50% drop in revenue, managed to far surpass 2023's EBIT over the nine months. Lasit also deserves a more precise mention, the company active in laser marking, which, after the potential sale of El.En.'s laser cutting business to YOFC, will remain the most significant business in our industrial sector. As we shared in earlier releases and meetings, this industrial business's profitability, in terms of both sales margins and EBIT margin, resembles more closely the profitability profile of the medical sector, historically within our group, far above the industrial one. During the past nine months, Lasit's revenue increased by over 12%, and the annual revenue projection is now put at approximately EUR 30 million. We're enthusiastic about the growth opportunities in this market segment and are actively backing its expansion with an aggressive internationalization strategy that includes setting up local distribution subsidiaries.

Andrea Cangioli

executive
#7

We already have subsidiaries established in Poland, Germany, Spain, and the U.K., and additional ones will follow so that we achieve the most effective coverage possible across the most interesting and promising outlet markets. Lasit's profitability across the first nine months came in below what we had anticipated, owing both to the softer Italian market and to the ramping up of some significant deals that land in our Q3 as work in progress and will add to sales and margins only in Q4. Following a slow beginning, the medical business showed a progressive recovery and is now headed toward a strong close of the year. A number of general economic environment complexities are rendering this year less favorable in the medical market, in particular the high interest rates, which always work against the market's willingness to purchase capital equipment, along with the unrest in certain geographical areas. We concentrated on traditional business levers, the release of new innovative products, which are always abundant, and marketing and commercial support for expanding the international footprint of our distributors. Notable positive trends were reported in the urology market, with continued success for Quanta System, both for new systems and for the consumable flow, and in the anti-aging application of the aesthetic business, where the DEKA products of the new line, namely the RedTouch PRO and the Onda PRO — the former for rejuvenation and pigmented lesions, and the latter for body contouring and skin and facial tightening — are meeting increasing market acceptance.

Andrea Cangioli

executive
#8

We've also brought out new products for the hair removal market, such as Again PRO from DEKA, MeDioStar Red Edition from Asclepion, Echo, and Suprema from Quanta System, and these allow us to keep a strong, leading competitive position in a market application segment that recently hasn't shown the same level of vitality as the other segments of medical aesthetics. The innovative processes that let the group strengthen its product range and give customers attractive, cutting-edge solutions stay central to the group's activities, strategic priorities, and investments. Medium-term forecasts for growth in target markets remain positive, and the group continues to count on their development. It deemed it essential to maintain substantial investment in research, development, and innovation in order to improve its competitiveness over time and seize the growth opportunity these markets offer. Over the course of the year, the group carried on its sustainability-oriented activities, adopting, among other things, the new five-year plan for 2023 to 2027, which sets out specific and measurable sustainability activities and objectives, addressing sensitive issues such as climate change mitigation, circular economy, promotion of a responsible supply chain, enhancement of individual contribution, and community support. The group reaffirms its continuing commitment to sustainable development, where environmental and social responsibility are increasingly integral to its business model.

Andrea Cangioli

executive
#9

During the quarter, and immediately after it closed, two notable developments occurred, and I'd like to say a few words about them before I pass the call to Enrico. At the close of August, Otlas bought back 100% of the shares of Cutlite Penta — the shares that Penta Laser (Zhejiang) held — thereby helping Cutlite Penta achieve a clearer separation from its Chinese sister companies, which, purely for the purpose of the possible IPO, had been permitted to exercise control over Cutlite Penta. After that, Penta Laser (Zhejiang) went ahead and liquidated the private equity funds that had put money into its capital. Under the terms set out in the original capital increase agreement, investors were repaid the capital they had invested along with interest, for a total of CNY 151 million, roughly EUR 19.4 million, which cleared Penta Laser's shareholder base of the financial investors that had been oriented solely toward the IPO. Then, last week, we announced the signing of a framework agreement with Yangtze Optical Fiber and Cable Joint Stock Limited Company, YOFC, headquartered in Wuhan, concerning the potential sale of a majority stake in the companies making up EL.En.'s laser cutting business, specifically Cutlite Penta and Penta Laser (Zhejiang).

Andrea Cangioli

executive
#10

Beyond the financial figures already covered in the press release and in Monday's call remarks, I'd like to give a little extra context on how this proposed strategic transaction is going to affect the business of our sole companies. EL.En. proceeded on the view of YOFC as a valued partner for handing over responsibility for operating one of its technological and business jewels, and that view rested on a set of significant values and capabilities that YOFC possesses and embodies. As a large corporation in very sound financial shape that is seeking diversification of its business, through this proposed transaction YOFC aims to diversify into the promising market of laser systems for manufacturing, and also potentially to integrate with its startup, Everfoton, which is engaged in developing and manufacturing fiber laser high-power laser sources, thereby sustaining rapid expansion of the business unit and capitalizing on the intrinsic core values of both the Italian and the Chinese companies. Seen in this light, the distinctive identity of Cutlite Penta — a market leader whose strong brand identity is tied to design, management, and manufacturing that are fully Italian — was a key factor in the stunning revenue growth Cutlite managed to achieve in the very last year.

Andrea Cangioli

executive
#11

Such elements form the bedrock of YOFC’s strategy, since the company is resolutely dedicated to witnessing a stronger Italian Cutlite in both its market effectiveness and its Italian identity, lifting its technical and commercial standing toward excellence on the world stage. I’ll return to the team later, and now I pass the call to Enrico Romagnoli.

Enrico Romagnoli

executive
#12

Thank you. Good morning, everyone. I'll make a brief remark about the nine-month financial result. For the first nine months of 2024, group revenues came in at EUR 466.2 million, a decline of 5.4% versus the same period of 2023. During this period, we saw sales fall in the industrial sector, -16%, while the medical sector grew by 2.1%, closing the gap with the prior year present through last June. months EUR 190.3 million, up from EUR 187.2 million in 2023, with sales margin recovering from 38%-40.8%. The gross margin improvement comes EUR 1.9 million, equal to 0.4 percentage points on turnover, from insurance proceeds and government reimbursement related to damage caused by the November 2023 flood in Campi Bisenzio. Excluding those proceeds, the period margin still improved by 2.4 percentage points versus 2023, thanks to a more favorable sales mix, both by product type and destination market within each sector, and thanks to the greater relative weight of the medical sector. Operating expenses rose and their impact on sales went up from 9%-9.7%, and the main reason is the sales and marketing expenses for trade fairs and congresses incurred by both the medical and industrial companies.

Enrico Romagnoli

executive
#13

Staff cost went up by EUR 2.2 million plus 2.7%, and its impact on sales runs from 16.4%-17.8%. The non-cash charge for stock option plans benefiting employees came to EUR 2.1 million in the period, versus EUR 2.5 million in the first half of 2024. EBITDA reached EUR 61.9 million, in line with the last year, with the impact on revenue up from 12.6%-13.3%. Depreciation and provision cost rose from EUR 10.1 million to EUR 11.1 million, and the impact on turnover grew from 2%-2.4%. This cost item's increase was driven by higher provisions for credit risk, both general and especially the specific provision of EUR 2 million set aside because of the sudden financial crisis of an important customer of our Japanese subsidiaries with us. The less unfavorable guarantee condition granted on the sales of a laser cutting system in China allowed a partial release of the product warranty provision, while the risk provision came down following the positive resolution of some disputes by Asclepion. EBIT posted a positive balance of EUR 50.8 million, down 1.7% from EUR 51.8 million registered in the last year, with a margin on sales at 10.9%, improving on last year's figure.

Enrico Romagnoli

executive
#14

We posted a net financial loss of EUR 1.6 million, versus a loss of EUR 0.9 million in the same period a year earlier. The reasons were a larger negative exchange difference during the period and more interest paid on loans, mainly taken out by the companies active in the industrial laser cutting sector, plus interest paid on the capital increase of venture capital payback by Penta Wenzhou in September 2024. The exit of private equity funds from the capital of Penta Zhejiang made it impossible to complete the company IPO on the Chinese market. Under the clauses of the contract through which, in 2019, the group bought the Penta Zhejiang shares held by the JV's minority partner, listing by November 2024 was the condition for paying an earn-out of EUR 5 million to the liquidated partner. Management therefore remeasured the financial liability under the IFRS 9 standard, recognizing a non-operating other income of EUR 5 million in profit or loss. As a result, income before taxes came in at a positive EUR 53.8 million, compared with EUR 50.8 million last year. During the period, the net financial position rose by EUR 19 million, reaching EUR 73.8 million at the end of September.

Enrico Romagnoli

executive
#15

During Q3, revenues grew overall, driven by a rise of more than 10% in the medical sector, while the industrial sector declined 6% and the cutting division fell 10%. Margins are improving, consistent with the nine-month trend. Turning to cash flow, the group's net financial position, as I mentioned, rose by EUR 19 million over the nine months, and the group also generated cash in Q3, to the tune of EUR 5 million. Net income flow from operating activities, along with depreciation and allowance, came in above EUR 44 million, which was used to increase working capital by EUR 19 million, to pay dividends of EUR 17 million, and for CapEx of EUR 11 million. The partial disposal of investments in liquidity recorded in non-current assets during Q2 added EUR 16.3 million to the net financial position for the period. The residual fair value of liquidity investments still recorded in non-current assets stands at EUR 7.5 million. The remeasurement on the net financial position debt, stemming from the expected expiration of the earn-out clause that obligated Otlas to pay EUR 5 million to the previous partner of the Chinese JV should Penta Laser (Zhejiang) complete a successful IPO by the end of 2024, also had a positive effect on the net financial position of EUR 5 million, since that amount had been accounted as a financial liability in the previous net financial position.

Enrico Romagnoli

executive
#16

Turning to how revenue splits across our businesses: medical sales rose 2.1% in 2024, helped by a solid Q3 2024 performance. Industrial sales moved the other way, falling 16%, largely because of the cutting division. During the third quarter, within medical, every medical segment grew apart from dental. That also let us post overall growth for the nine months as well. Post-sales revenue is doing much of the work behind the medical increase, coming in at EUR 59 million, up 13%. Systems revenue stayed level with the prior year: esthetic brought in EUR 165.7 million, matching last year's figure, while surgery came to EUR 56.4 million against EUR 55.9 million in the same period of 2023. Optical fiber consumed in urological surgery made a strong contribution to sales, accounting for 40% of sales in the goods and after-sales services segment. In industrial applications, revenue declined, chiefly because market conditions in the cutting sector were unfavorable in key markets, namely China and Italy. The laser cutting segment posted revenue of EUR 130.5 million versus EUR 166.2 million in the first nine months of 2023.

Enrico Romagnoli

executive
#17

Revenue and order acquisition trends in Italy were quite soft during the first half of the year. Growth in services revenue stayed robust, which directly mirrors the sizable rise in the number of systems installed over the past years. Laser source sales held steady, in line with the laser market segment. Geographically, the biggest growth came in Europe across both sectors. In Europe's medical sector, we posted 6% growth, while sales in the rest of the world match those of the prior year. On the industrial side, performance in the international market was clearly strong, with robust growth in Europe of plus 16%, while the rest of the world recorded a slight decline, mainly because of a substantial reduction in China alongside rapid development across all other markets, especially the USA. The Italian market remained weak, especially in the industrial sector, which experienced a 42% drop in sales. That said, Italy's medical sector recovered slightly, showing a minimal decrease versus the previous year. Andrea, please continue with the guidance.

Andrea Cangioli

executive
#18

Alright. So the Q3 2024 financial results and those for the nine months are consistent with the guidance we have now, and profitability recovered in a way that puts EBIT for the first nine months of 2024 very near where it stood in the same period of 2023. We made a commitment to explain to you how the way our financial results are reported might change as a result of the proposed sale of the laser cutting business unit, and how that different representation affects our guidance. The net financial results of the activities available for sale — that is the proper definition under financial reporting — will remain with us until the definitive final share purchase agreement, if and when those activities are executed and registered in the respective jurisdictions. Until that point, revenues and costs tied to such activities for the whole of 2024 will be reclassified into a single reporting line in the P&L, positioned below the EBIT line. So, should the cutting business be sold, 2024 consolidated revenues and EBIT will contain only the medical sector and the remaining portion of the industrial sector. To keep things simple, and to avoid needless and complicated additions and subtractions, we chose to keep the reference for that guidance on our current consolidation perimeter so it is comparable to the new representation of our financials.

Andrea Cangioli

executive
#19

When it comes to 2025, the guidance will be adapted to the new perimeter. However, since the net results of the divested companies will still be feeding into our net consolidated results through the end of 2024, our guidance will keep referring to the original aggregate. To make it possible to assess whether the guidance target has been achieved, we will offer a suitable pro forma representation. Against that backdrop, we confirm our expectation of higher operating profit for 2024 than in 2023, although the downturn in the cutting sector will keep consolidated revenue from matching the record results posted in 2023. That concludes our prepared remarks, so we are now ready to take your questions in the Q&A session.

Operator

operator
#20

Andrea.

Andrea Cangioli

executive
#21

Hello there. Yes, I’m able to hear you.

Operator

operator
#22

We'll now begin the question-and-answer portion.

Andrea Cangioli

executive
#23

All right, may I begin?

Operator

operator
#24

Giovanni Selvetti from Berenberg has the first question. Please go ahead, Giovanni.

Andrea Cangioli

executive
#25

Hello there, Giovanni.

Giovanni Selvetti

analyst
#26

Hi Andrea, hi Enrico, and congratulations on the results. I have a few questions, some of them quite short. First, I was hoping you could update us on Accure Acne and how the acne treatment is progressing. There hasn't been much discussion about it recently, so I'm curious where things stand. From what I recall, the company was beginning some trials in the U.S., but I'd like to know whether any revenue is being generated now, and if not, when it is expected to begin contributing to the business. Second, on net financial charges, of the EUR 1.1 million of negative charges in Q3, how much is FX related and mainly dollar related? In other words, how much of this can we expect to reverse in Q4? Third, perhaps on Industry 5.0 — I know the cutting division is now potentially for sale, but I was just wondering whether you can give us an update there. On the last call, you mentioned that in the early days of September you had started to see the order book piling up.

Giovanni Selvetti

analyst
#27

If these trends carry on, then. And I have two others, though perhaps I’ll simply ask later if there are no further questions.

Andrea Cangioli

executive
#28

All right, Giovanni, thanks for those questions. Accure Acne is still going, and it's dealing with the fact that it couldn't raise the capital it had wanted in order to grow its business. So they've begun selling a product that, to be sold, requires a massive marketing push — or, to put it better, would require a massive marketing spend and effort, and it's very risky as well. So right now they are selling, but the volumes aren't what people might have expected a few years back. My belief is that by year-end, we'll see a few million in revenue at Accure Acne, and correspondingly at Quanta System, which, as you know, supplies the product. Ironically, the reason Accure Acne couldn't take off in the market the way we'd planned comes down to what our competitor did — they were extremely, extremely active and extremely successful in getting ahead of Accure Acne's release by bringing to market a rival system named AviClear. I'm referring to Cutera, a company based in the U.S., which made a substantial bet on this product, offering it to the market at essentially no financial charge, putting in a huge amount of money — again, a bet on this product's success.

Andrea Cangioli

executive
#29

I say that ironically, since it doesn't appear that this strategy has given Cutera any edge, at least as of today. Over the last two years, its capital — its market capitalization — has dropped from more than $1 billion down to $7 million at today's value, because that very aggressive policy brought in no cash for them. What it brought them was a lot of losses. Having a supposedly equivalent system available on the market at a far lower cost actually did great damage to Accure Acne. We'll see how this development phase at Cutera continues. Right now, we keep supporting Accure internationally as well. There's a meeting today where Accure is being presented at a small congress to a few tens of doctors. We are promoting it, but we aren't expecting any transformation in Accure's volumes in 2025 either. As for the interest, I think it's mostly due to the Chinese payment to the private equity funds, but on the interest, Enrico can probably answer better than I can.

Enrico Romagnoli

executive
#30

Right, so regarding the forex effect, the nine months shows a negative impact of EUR 0.4 million from foreign exchange loss. In the same nine-month period last year, the effect was positive at EUR 0.2 million. Also, during the nine months of 2024, there was a one-time cost tied to the venture capital that signed a waiver concerning the buyback of the capital increase in Penta Laser Wenzhou. That one-time cost amounts to EUR 0.6 million and had not previously been accounted for in the P&L of Penta Laser Zhejiang.

Andrea Cangioli

executive
#31

You also asked Giovanni about what we anticipate going forward regarding foreign exchange accounting, considering how strongly the U.S. dollar has strengthened over these past weeks, and considering that we typically carry a fairly sizable receivables balance because of the solid business we have in the United States. My expectation, assuming nothing shifts suddenly, is that foreign exchange will be positive. Foreign exchange effects will be positive. Per piacere. Maybe you, as host, can mute that line. No, actually I have them all turned off, I don't understand which one it is. His name is Michele Campagnoli. Coming back to your question, Giovanni. 5.0, yes. We're observing better traction in the Italian market after the summer period. The ministerial clarifications came out on how 5.0 could be applied, and they removed every doubt from the table. This, as I've mentioned at other meetings, produces a twofold effect. It doesn't only clarify the scope and the size of the incentives, which therefore lets a number of our customers benefit from the incentive, but it also eliminates and clears away all the uncertainty that existed since, with nobody knowing how this would function, nobody dared to place an order before those explanations were circulated, because they worried that placing an order too soon would have put them at risk of missing the opportunity.

Andrea Cangioli

executive
#32

So at this point, whether or not they go ahead — now they're informed, and when they place an order, some will include the 5.0 and some won't — but the danger of being disqualified over a procedural error is gone. That's why I can confirm that right now, alongside the rapid international sales growth we're seeing at Cutlite Penta and, at this moment, at Lasit as well, we're also observing a recovery in order bookings within Italy.

Giovanni Selvetti

analyst
#33

All right, thanks. Perhaps we’ll hold the remaining two questions until everyone else has gone. Thanks.

Operator

operator
#34

All right. Our next question is from Matteo Ghilotti at Equita. Matteo, please go ahead.

Matteo Ghilotti

analyst
#35

Thank you. Good afternoon. My first question concerns the sharp acceleration in the service line within the medical business. If I understood correctly, this is somewhat one-off in nature, since it rose 6% during the first six months and is now up 13%, which is very, very, very good. If I have that right, we shouldn't extrapolate that. Is it more of a one-off, or not? And the second question is, sorry, quite a trivial one about 2025. Just drawing on your experience and your gut feeling, do you believe it can be a year in which your business is able to expand? Too early to say — just a qualitative answer is perfect. Thank you.

Andrea Cangioli

executive
#36

Service keeps getting better. That always occurs when they—driven by the installed base—and we've got a second factor at play here too, namely growth in consumables, so it's possible we won't manage to sustain this rate of growth for very long, though we're certainly putting in the effort to do so. To offer one illustration, over the first nine months of this year we acquired part of a building close to Quanta System, where we're relocating a larger clean room so as to boost and expand our capacity for producing optical fibers, and optical fibers account for roughly 40% of service sales and make up the portion of service sales that is rising fastest. So predicting an aggregate like this is hard, but we're working to keep it growing and to ensure it remains a significant and expanding piece of the business. As for 2025, all I can tell you is that we understood we were projecting a trend for 2024 that anticipated higher order bookings and revenues moving into the second half of the year, and that is in fact happening now—so that's where things stand.

Andrea Cangioli

executive
#37

I mean, from what we can observe right now, the projections we made have come through. We're moving into budget season at this point, so we're having the initial formal discussions regarding what 2025 is going to look like, and of course feelings are mixed. We're aware that certain things will keep the recovery trend going, so we feel quite positive. We're aware that certain things will be softer. We're aware that a few businesses will in all likelihood remain unchanged. So I can tell you there's general optimism about where our markets are heading, but right now I'm not in a position to offer anything more precise than that.

Matteo Ghilotti

analyst
#38

Okay, that's fair. Thanks.

Andrea Cangioli

executive
#39

No problem at all.

Operator

operator
#40

Andrea Bonfà from Banca Akros has sent in question number three. Please proceed, Andrea.

Andrea Bonfà

analyst
#41

Good afternoon, everyone, and I hope I’m coming through clearly. Most of what I wanted to ask has already been covered, though perhaps you could say a bit more about how urology is doing inside the medical division, since that has historically been a business growing at a double-digit rate. Thank you very much.

Andrea Cangioli

executive
#42

Thanks, Andrea. Yeah, urology has typically been a market that grows at a double-digit pace. Growing double digits for four straight years, or even three in a row, isn't easy. If you look, surgical is up only 1%, but you're right. Right now I can't recall off the top of my head how much growth urology has posted. My sense is that urology's growth inside surgical is still in the single digits. We didn't reach double digits, but that 1% figure reflects growth in one segment set against declines in others, such as Monalisa Touch and surgical CO2s, during these nine months. So our confidence in urology remains strong, reinforced by innovation as well. As you know, Quanta System released a new product for sale in 2025 called Magneto, which brings improved characteristics in stone treatment. And naturally, a larger installed base of urology systems is also what drives the rising flow of fiber optic consumables, as we discussed in the earlier question.

Andrea Bonfà

analyst
#43

And if I can jump in here, Andrea, that growth we're seeing in fiber optics consumables production — is that mainly tied to the consumables used in urology, or is it something else?

Andrea Cangioli

executive
#44

Yes, yes, absolutely. 100%. Well, let's say this: the fiber optics manufacturing facility is entirely devoted to urology. The reason is that urology — along with other surgical specialties, though our sales are mostly in urology — requires either a single-use fiber or one of the uses of a multi-use fiber for every single surgery that gets done. And so, because the application is very popular, we sell a lot of lasers since the application is very popular. So every laser gets used for tens of surgeries per day or per week. Fiber optic consumption is high as well. And fiber optics are contributing very well at revenues and also thanks to certain cost savings that we placed in the fibers production line, also in terms of margins.

Andrea Bonfà

analyst
#45

I really appreciate it.

Operator

operator
#46

Andrea, we have another question, and it's from Carlo Maritano at Intermonte. Carlo, go ahead, please.

Carlo Maritano

analyst
#47

Good afternoon, everyone. I have just one quick question. On Monday, you gave us a sense of the EBIT for the first half of the cutting business. I was wondering whether you have a sense of the nine months of this business, just to help us with the analysis of the perimeter after the deal. Thank you.

Andrea Cangioli

executive
#48

We're aware of that as well. Like I mentioned, it has been rising compared with last year, though it remains within the same order of magnitude. The figure is under 2 million.

Carlo Maritano

analyst
#49

Thanks.

Operator

operator
#50

Andrea, right now there are no further questions in our queue.

Andrea Cangioli

executive
#51

Giovanni was interested in asking additional questions.

Operator

operator
#52

Please proceed, Giovanni.

Giovanni Selvetti

analyst
#53

I've got a few more. Perhaps regarding optical fibers — I was curious whether every fiber you sell goes solely into Quanta or, say, El.En. products, or whether you're also able to supply them for, let's say, Olympus laser systems or those of other competitors. Is there an opportunity to do that, since that way you could sell even if, let's say, the installed base doesn't grow. The second one is sort of an update. I recall that early in the year you flagged a legal dispute in China concerning delivery of a laser system, and I probably missed it, but I was wondering whether there's any update there, and maybe the last one concerns Asclepion, which historically, well, at least over the last year, had more trouble than the other companies in the group sourcing some materials. So, if all those issues are resolved and Asclepion is up and running again, thank you.

Andrea Cangioli

executive
#54

Thanks, Giovanni. Three responses. On fibers: we supply fibers both to our customers and to OEM customers—Olympus among them—and Olympus turned into a rival once it began working with a different OEM manufacturer as well. In principle, every manufacturer seeks to supply optical fiber to its own customers and seeks to shield its own customers from purchasing fibers—not from rivals. It isn't typical, but from pure fiber makers. Since, I mean, some fiber manufacturers could potentially create a product compatible with ours. To counter that, we likewise hold protection on specific products and specific product lines. We have RFID protection on the fibers, which keeps our customer entirely captive. The China dispute. The China dispute, despite their claim that the Chinese court would settle the matter within three months, since the Chinese are highly efficient, remains ongoing. It's a lengthy dispute. We haven't received any resolution from the judge as yet, even though there has been an assessment—a technical assessment—of the capability of the system we supplied to effectively meet the specification where we had issues. But we don't know how that assessment will be read, understood, and converted into a ruling by the judge.

Andrea Cangioli

executive
#55

Because this deal sits inside the cutting division that’s being sold, that’s one of the indemnity points we’re talking over with the prospective buyer — so we carry a certain financial representation of this matter in our financials, and if the outcome turns out otherwise, that would result in an adjustment to the selling price of the companies. On Asclepion, it’s a good question, since Asclepion unfortunately couldn’t fully take advantage of the very strong years, 2022 and 2023, because of the persistent shortage issues that hit Germany much harder than Italy. I’d say the picture in Germany now is entirely different. As of today, Asclepion is performing very well and has no production issue. Our bigger concern is the overall situation in Germany, which is a very important market for Asclepion, and the overall management of the country and of the company itself, which need a rapid improvement in performance. That’s because Asclepion’s performance was okay in these months, but it wasn’t at par with the other companies in the medical business.

Operator

operator
#56

Andrea, there are a few additional questions we want to get to. Jonas Liegl from Lupus alpha has the first one. Please go ahead, Jonas.

Jonas Liegl

analyst
#57

Thanks so much, Andrea. I was curious about how you're viewing possible effects from U.S. import duties under the new administration we now have? Do you have any plans to get ready when it comes to having a local presence in the U.S.? Maybe some general thoughts on that subject, and also if you could remind us of your present sales exposure to the U.S. and whether any direct competitors might hold an advantage over you if new import duties come in?

Andrea Cangioli

executive
#58

Hi there. This is a fairly detailed response, since it differs across the various sectors. There are multiple domestic producers of medical laser systems in the United States, yet the country also depends on a substantial volume of imported medical devices. So my view is that, should tariffs rise, domestic manufacturers would gain considerably, as they currently account for only a modest share of the market. That's also because the production base for several brands that sell heavily in the USA sits abroad. Production happens in Israel, happens in Korea, happens in Europe, and happens in the United States as well, though not in every case. So there would definitely be a negative impact from that. But we wouldn't be — I mean, my belief is that domestic manufacturing in the United States couldn't fully support the market. As for the industrial side as a system, and here's another point, of course, should we establish a US subsidiary to sell our products? That would be a distribution subsidiary. It would make sense for us to make anything in the United States in the medical business, because costs there are so high that we would save. We would be better off, of course, depending on how far the tariffs go, but we'd be better off absorbing the tariffs than manufacturing highly expensive complex devices in a country like that — devices of the kind we ourselves sometimes barely manage to produce here, because the product is genuinely complex and hard to make.

Andrea Cangioli

executive
#59

When it comes to the industrial business—specifically the business we're proposing to sell, the cutting business—we're very active in the United States, and most of the international growth of Cutlite Penta, the Italian Cutlite Penta, comes from the United States. And so, we also have a related company selling—it's not a subsidiary, but with ours in the United States. So we're looking to reinforce our position in the market. On this, I believe that should tariffs be imposed, especially on the Chinese manufacturers, this would impact on our Chinese manufacturing base, but would be—since I would expect, I don't know, tariffs to be higher on Chinese products than on European products—would give a differential advantage to the European product. The good news here is that for what concerns laser cutting business, excuse me, laser cutting systems, there's a negligible manufacturing base in the United States. So all the products are imported. So if a tariff will be imposed, it will be eventually a burden for the U.S. market, but it will not create any advantage to local manufacturers because local manufacturers are not present at all. A third area of interest is the marking business, which following the proposed sales would remain the most significant business in the industrial sector within the El.En.

Andrea Cangioli

executive
#60

Regarding the Group: we’ve been selling modest volumes—under 1% of laser sales—into the United States, yet we intend to broaden our presence through subsidiaries there as well. After setting up the Western European subsidiaries—in Europe, in the European subsidiaries, Poland, Germany, the U.K., and Spain—I believe there’s a plan to proceed and shift to the United States. If we turn to tariffs, though, never for manufacturing. That way, we’d get a lower transfer price increase, because you’re not selling the product to the end user; you’re selling it to the distributor, who then sells it to the end user with a markup. As a result, the customs tariffs would be lower. Still, we aren’t seeking any way around the tariffs, since that wouldn’t be appropriate.

Jonas Liegl

analyst
#61

Thanks. And could you remind us what portion of the medical segment's sales comes from the U.S.?

Andrea Cangioli

executive
#62

It's a matter of a certain figure. I can't recall it right now offhand, but across the nine months, over the years, it's something that stays below EUR 40 million. Perhaps I might be able to, maybe I do know it. What I mean is, we've never given those numbers out in detail, though occasionally we offer little hints regarding the amounts. But no, it's simply, yes, within the medical business, yes, it will reach EUR 80 million this year.

Jonas Liegl

analyst
#63

All right, that's great. Thanks a lot.

Operator

operator
#64

Andrea, Giuseppe Mapelli from Equita has another question for us. Please proceed. Emmanuel, you're next.

Giuseppe Mapelli

analyst
#65

Thanks a lot. I just want to clarify something about Monday's conference call. Perhaps I'm mistaken, but if I got it right, you said that following the transformation of El.En. into an almost purely medical business, with the cutting business sold, let's say certain opportunities will come to the surface that, let's say, in some cases could be viewed as an enabler given their size. Did I understand that statement correctly, or am I wrong?

Andrea Cangioli

executive
#66

Sorry, no — I think what I said could be taken that way. What I meant is that historically, anyone considering our company either for valuation or as a possible combination ran into a problem: we were a company with two businesses, and combining with us is hard because you'd be combining with just one of them, or just the other. So with more of our focus on one single business, a potential combination becomes simpler. I also made the point that we aren't anticipating any particular M&A deal as a result of the boost to our net financial position that the transaction would produce, and that our attention stays on growing our activity from within, which we see as a major growth opportunity — investing in the activities themselves. That applies to our medical business — mainly the three companies in medical aesthetics and surgery, DEKA, Quanta, and Asclepion, plus the one in therapy — and it applies to laser as well. As I just mentioned, we intend to invest so that this business unit keeps growing inside the industrial sector.

Operator

operator
#67

Thanks. We have another question, this time from Emmanuel de Figueiredo at LBV. Please go ahead, Emmanuel.

Emmanuel de Figueiredo

analyst
#68

Good afternoon, everyone. This is really just a clarification, or a bit more explanation, regarding the potential tariffs from the U.S. From what I understand about the U.S. across many industries—though I'm not so familiar with the medical supply side, which is why I'm asking—a great deal of domestic production is actually located in Mexico. And with Trump, it remains quite unclear what will happen and what he'll do regarding Mexico. So my question is this: do some of your competitors, some of the U.S. ones, have production bases in Mexico? And if Trump doesn't impose tariffs on Mexico, would you think about opening something in Mexico? Thank you.

Andrea Cangioli

executive
#69

The first thing we need is clarity on how big these tariffs actually are, since unless they turn out to be enormous, setting up production capacity for a product at a location other than the one where we've always made it would in all likelihood be very complicated and expensive. As I mentioned earlier, this kind of manufacturing calls for a great deal of skilled labor, and replicating our lines wouldn't be feasible. Our products, unfortunately, are highly intricate, and they evolve rapidly. That means we require a very highly trained manufacturing floor in order to produce them. All of which is to say, I don't see us shifting manufacturing to Mexico. Some of our competitors, I think, do depend on Mexican production. I can't say with 100% certainty, but my understanding is that Cynosure, for example, does. That said, my belief is that the biggest share of medical devices sold within U.S. territory gets manufactured in Europe, Israel, and Korea. Those, then, are the regions that will be competing against us, situated alongside us, or that will endure the imposition of tariffs together with us. Domestic manufacturing—American-made products—matters today, but in the U.S. market, my belief is that it doesn't even account for 50% of the volume of products sold.

Emmanuel de Figueiredo

analyst
#70

Understood completely. Thanks so much.

Andrea Cangioli

executive
#71

Appreciate the question, Emmanuel.

Operator

operator
#72

Andrea, at this point our list shows no additional questions. If any investors are still on the line, I'd like to check whether anyone has anything further to ask. Since there are none, ladies and gentlemen, that brings the conference to a close. Should you have any questions you wish to look into going forward, please feel free to reach out to Enrico Romagnoli. He will be glad to respond to your inquiry. Thank you for joining this conference, and we hope to have all of you with us again next time. Good afternoon to everyone. Goodbye. Goodbye to all.

Andrea Cangioli

executive
#73

Bye-bye. Bye. Bye. Have a nice weekend.

Operator

operator
#74

The recording has ended.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.